Lakomek H J, Fiori W, Buscham K, Hülsemann J, Köneke N, Liman W, Märker-Hermann E, Roeder N
Klinik für Rheumatologie und Physikalische Medizin, Klinikum Minden.
Z Rheumatol. 2006 Feb;65(1):46-8, 50-1. doi: 10.1007/s00393-006-0034-7.
Starting with the second year of the so called "convergence period", specialized rheumatological treatment is now represented by a specific DRG (197Z) in the German G-DRG system. The definition of this DRG is based on the procedure codes for the complex and multimodal treatment of rheumatological inpatients (OPS 8-983 and 8-986). This will result in a more appropriate reimbursement of rheumatological treatment. The implementation of specialized rheumatological treatment can be regarded as exemplary for the incorporation of medical specializations into DRG systems. The first step is the definition of the characteristics by procedure codes, which can consequently be utilized within the grouping algorithm. After an inadequate representation of a medical specialization within the DRG system has been demonstrated, a new DRG will be established. As no cost data were available, the calculation of a cost weight for the new G-DRG 197Z is not yet possible for 2006. Hence, reimbursement has to be negotiated between the individual hospital and the budget commission of the health insurers. In this context, the use of clinical pathways is considered helpful.
从所谓“融合期”的第二年开始,在德国的G-DRG系统中,专门的风湿病治疗现在由一个特定的诊断相关分组(197Z)来体现。这个诊断相关分组的定义基于风湿病住院患者复杂多模式治疗的程序编码(OPS 8-983和8-986)。这将使风湿病治疗得到更合理的报销。专门的风湿病治疗的实施可被视为将医学专科纳入诊断相关分组系统的典范。第一步是通过程序编码定义特征,这些特征随后可在分组算法中使用。在证明诊断相关分组系统内某个医学专科的代表性不足之后,将建立一个新的诊断相关分组。由于没有成本数据,2006年还无法计算新的G-DRG 197Z的成本权重。因此,报销必须由各医院与健康保险公司的预算委员会协商确定。在这种情况下,临床路径的使用被认为是有帮助的。